| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 05/18/2007 | WO2007054182A2 Nanoparticles used as contrasting agents in magnetic resonance imaging |
| 05/18/2007 | WO2007054120A1 Identification and characterization of function-blocking anti-ed-b-fibronectin antibodies |
| 05/18/2007 | WO2007053946A1 Method of treating diabetes and/or obesity with reduced nausea side effects using an insulinotropic peptide conjugated to albumin |
| 05/18/2007 | WO2007018622A3 Vaginal treatment composition |
| 05/18/2007 | WO2007014784A3 Antitumoral bioconjugates of hyaluronic acid or its derivatives obtained by indirect chemical conjugation |
| 05/18/2007 | WO2007008778A3 Formulations for enhanced mucosal delivery of pyy |
| 05/18/2007 | WO2006122223A3 Strategies for delivery of active agents using micelles and particles |
| 05/18/2007 | WO2006114105A3 Use of modified factor vii for treating bleeding |
| 05/18/2007 | WO2006077597A3 Novel neuroprotective compounds and uses thereof |
| 05/18/2007 | WO2006042848A9 Growth hormone conjugates |
| 05/18/2007 | WO2006020719A3 Aminoacid conjugates of beta - lapachone for tumor targeting |
| 05/18/2007 | WO2005085457A3 Method and products for the selective degradation of proteins |
| 05/18/2007 | WO2003076594A3 Genomic screen for epigenetically silenced tumor suppressor genes |
| 05/18/2007 | CA2629487A1 Intraorally rapidly disintegrating tablet |
| 05/18/2007 | CA2628552A1 Identification and characterization of function-blocking anti-ed-b-fibronectin antibodies |
| 05/18/2007 | CA2628305A1 Jelly composition |
| 05/18/2007 | CA2628272A1 Polycation-polyanion complexes, compositions and methods of use thereof |
| 05/18/2007 | CA2628113A1 Peptide-dicer substrate rna conjugates as delivery vehicles for sirna |
| 05/18/2007 | CA2626961A1 Phospholipase inhibitors, including multi-valent phospholipase inhibitors, and use thereof, including as lumen-localized phospholipase inhibitors |
| 05/18/2007 | CA2626894A1 Stabilized lanthanum carbonate compositions |
| 05/17/2007 | US20070112176 Lipid membrane structure containing anti-mt-mmp monoclonal antibody |
| 05/17/2007 | US20070112064 Nucleic acid antioxidant compositions, methods for obtaining such compositions and formulations thereof |
| 05/17/2007 | US20070111940 Peptide agonists of GLP-1 activity |
| 05/17/2007 | US20070110811 Methods for reducing the mitogenicity of lectin compositions |
| 05/17/2007 | US20070110809 Stabilised compositions |
| 05/17/2007 | US20070110806 Core contains acid-unstable drug and disintegrant, and release-controlling coating contains water-insoluble polymer, an enteric polymer and hydrophobic wax; capsules |
| 05/17/2007 | US20070110804 Drug polymer complexes |
| 05/17/2007 | US20070110801 Method for the diffusion of molecules which are insoluble in an aqueous medium and composition using said method |
| 05/17/2007 | US20070110800 Pharmaceutical composition having uniform drug distribution and potency |
| 05/17/2007 | US20070110797 Methods and Compositions For Topical Wound Treatment |
| 05/17/2007 | US20070110769 Clostridial toxin derivatives and methods for treating pain |
| 05/17/2007 | US20070110762 Process for preparing polysaccharide-protein conjugate vaccines |
| 05/17/2007 | US20070110736 Mixture comprising mannitol for suspending animal or human cells and for dissolving biologically active molecules in order to introduce molecules into cells using electric current |
| 05/17/2007 | US20070110734 Methods and compositions using cellular asialodeterminants and glycoconjugates for targeting cells to tissues and organs |
| 05/17/2007 | US20070110733 Compositions and methods for stem cell delivery |
| 05/17/2007 | US20070110709 Water-soluble stabilized self-assembled polyelectrolytes |
| 05/17/2007 | US20070110677 Delivery of drugs to mucosal surfaces |
| 05/16/2007 | EP1785422A1 Micronised crystalline tiotropium bromide |
| 05/16/2007 | EP1785156A1 Pharmaceutical compositions |
| 05/16/2007 | EP1785145A1 Transnasal composition having immediate action and high absorbability |
| 05/16/2007 | EP1785144A2 Combinations of bile acids sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
| 05/16/2007 | EP1785141A1 Stabilized lanthanum carbonate compositions |
| 05/16/2007 | EP1785138A1 Mitochondria activators |
| 05/16/2007 | EP1785131A1 External preparation of s/o type |
| 05/16/2007 | EP1784430A1 Living radical polymerization initiator comprising a functional group capable of reacting with polyeptides or the like, comb polymer obtained therewith , polypeptide conjugates and drugs obtained therefrom. |
| 05/16/2007 | EP1784427A2 Bispecific fusion antibodies with enhanced serum half-life |
| 05/16/2007 | EP1784226A2 Cyanine dyes conjugated with antibodies for the diagnosis of micrometastasis |
| 05/16/2007 | EP1784225A2 Biomimetic of evodia rutaecarpa fruit extract for amelioration of inflammation |
| 05/16/2007 | EP1784215A1 1,4 o-linked saccharose derivatives for stabilizing antibodies or antibody derivatives |
| 05/16/2007 | EP1784202A1 Ejection liquid, ejection method, method for forming liquid droplets, liquid ejection cartridge and ejection apparatus |
| 05/16/2007 | EP1784172A2 Cancer chemotherapy |
| 05/16/2007 | EP1784169A1 Polymeric adhesive matrix with salified carboxylic groups for transdermal use |
| 05/16/2007 | EP1784168A1 Method of use herbal compositions |
| 05/16/2007 | EP1784165A1 Stable particle formulations of erythropoietin receptor agonists |
| 05/16/2007 | EP1784160A1 Controlled release formulations of enzymes, microorganisms, and antibodies with mucoadhesive polymers |
| 05/16/2007 | EP1784133A2 Embolization |
| 05/16/2007 | EP1539201A4 Antipyrotic and method of manufacturing the same |
| 05/16/2007 | EP1536807A4 Non-polymeric hematopoietic cell clots for delivery of active agents |
| 05/16/2007 | EP1455805B1 A process for obtaining a zinc oxide containing product for skin-healing, care and protection in children and adults |
| 05/16/2007 | EP1455605B1 Soft drink replacer |
| 05/16/2007 | EP1372700B1 Stable aqueous solutions of granulocyte macrophage colony-stimulating factor |
| 05/16/2007 | EP1355928B1 Universal carrier for targeting molecules to gb3 receptor expressing cells |
| 05/16/2007 | EP1263347B1 System for the controlled delivery of an active material to a dental site |
| 05/16/2007 | CN1965082A 人源化抗体 Humanized antibodies |
| 05/16/2007 | CN1964744A Delivery system for bioactive agents on the basis of a polymeric drug carrier comprising an amphiphilic block polymer and a polylacticacid derivative |
| 05/16/2007 | CN1964743A Stabilized compositions comprising a therapeutically active agent, citric acid or a conjugated base and chlorine dioxide |
| 05/16/2007 | CN1964739A Uses of anti-CTLA-4 antibodies |
| 05/16/2007 | CN1964699A Dry-form composition for oral ingestion and gel-form composition for oral ingestion of type prepared at time of use |
| 05/16/2007 | CN1964698A Pharmaceutical compositions comprising polyethylene glycol having a molecular weight of less than 600 daltons |
| 05/16/2007 | CN1962697A Sp. PCC exocellular polysaccharide preparation and its uses as thickener and emulsifier |
| 05/16/2007 | CN1962695A GLP-1 infusion proteins, their preparation and use |
| 05/16/2007 | CN1962693A Long-acting thymosin alpha1 polyethylene glycol modifier |
| 05/16/2007 | CN1962683A Polyethylene glycol modified sterol copolymer and its uses |
| 05/16/2007 | CN1961962A Amphiphilic tri-block copolymer taxol bonding medicament and synthesis method thereof |
| 05/16/2007 | CN1961961A A pharmaceutical formulation and preparation process thereof |
| 05/16/2007 | CN1961960A Method for preparing magnetic macromolecular microsphere of crosslinking dialdehyde starch |
| 05/16/2007 | CN1961959A Method for preparing hollow fiber with temperature sensitive medicinal hydrogel and application thereof |
| 05/16/2007 | CN1961892A Dalbergia wood and beta-cyclodextrin inclusion compound, formulation thereof and preparation method thereof |
| 05/16/2007 | CN1961874A Pharmaceutical composition of Silybin and preparation method thereof |
| 05/16/2007 | CN1961865A Injection liquid of adenosine triphosphate magnesium and preparation method thereof |
| 05/16/2007 | CN1961864A Anticancer composition |
| 05/16/2007 | CN1961863A An anticancer sustained releasing agent containing mesenchyme hydrolytic reagent and cytotoxic drug |
| 05/16/2007 | CN1961862A Compound anticancer sustained releasing agent containing mesenchyme hydrolytic reagent |
| 05/16/2007 | CN1961861A An anticancer sustained releasing agent |
| 05/16/2007 | CN1961860A A solid tumor resistant tumor |
| 05/16/2007 | CN1315869C Osteoporosis resistant estrogen-RGD peptide conjugate and its application in medicine |
| 05/16/2007 | CN1315867C 17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents |
| 05/16/2007 | CN1315850C Axial substituted phthalocyanine compound, its preparation and application in optical kinetic treatment |
| 05/16/2007 | CN1315531C Remedies for dry eye and diseases associated with dry eye |
| 05/16/2007 | CN1315530C Method of preparing system for controlled release of medication in protein category |
| 05/16/2007 | CN1315483C Compositions internal or relevant improvement |
| 05/15/2007 | US7217846 Multilayer crystal structure containing guest molecule; encapsulation of a fluid; transferring; supplying hydrogen, methane as fuel |
| 05/15/2007 | US7217845 Bifunctional polyethylene glycol derivatives |
| 05/15/2007 | US7217833 May be used to prepare novel aerosol formulations, and can be advantageous in terms of improving the stability of the aerosol formulation, reducing drug deposition, increasing shelf life |
| 05/15/2007 | US7217819 Immobilization of taxane; anticancer, antitumor agents |
| 05/15/2007 | US7217788 Controlling immunology; antiinflammatory agents |
| 05/15/2007 | US7217770 Stable polymeric micelle-type drug composition and method for the preparation thereof |
| 05/15/2007 | US7217457 Mixture of hydrophobic polymer core and nanoparticles; immobilization |
| 05/15/2007 | US7217431 Controlled agglomeration |
| 05/15/2007 | US7217426 Forming a coating on the device, the coating including a polycationic peptide; and treating the coating with a stimulus that cleaves peptide bonds for enriching a region close to the outer surface of the coating with the polycationic peptide |